Floatz logo

Rapamycin

Recurrent Childhood Acute Myeloid Leukemia

Federal Research Institute of Pediatric Hematology, Oncology and ImmunologyPhase 2/3Active
BB
64/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
56/ 100
Competitive Position
81/ 100

Competitive context

13 Active assets in the Recurrent Childhood Acute Myeloid Leukemia cohort.

Asset / SponsorPhaseRating
ETOPOSIDE
Joanna Yi
Phase 3BBB
Cyclophosphamide
Joanna Yi
Phase 3BB
FILGRASTIM
Washington University School of Medicine
Phase 3BB
Romidepsin
Washington University School of Medicine
Phase 3BB
Fludarabine
Joanna Yi
Phase 3BB

View all 43 →

Same molecule, other indications

Rapamycin is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →